|Bid||86.27 x 900|
|Ask||86.28 x 1100|
|Day's range||85.46 - 86.47|
|52-week range||66.10 - 87.07|
|Beta (3Y monthly)||0.32|
|PE ratio (TTM)||24.19|
|Earnings date||29 Oct 2019|
|Forward dividend & yield||2.20 (2.59%)|
|1y target est||94.93|
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women Who Responded to Platinum-Base
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Does the August share price for Merck & Co., Inc. (NYSE:MRK) reflect what it's really worth? Today, we will estimate...
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
Merck (MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum has been promoted to vice president, Investor Relations, effective Aug. 19, 2019. Teri Loxam, senior vice president, Investor Relations and Global Communications, will be leaving Merck to become chief financial officer of SQZ Biotech. “Merck has benefited from Teri’s leadership and skilled and principled approach to communicating with its many constituencies including those in the financial community.
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
AstraZeneca and Merck’s LYNPARZA Improved Radiographic Progression Free Survival vs. Standard of Care in Patients Selected for BRCA 1/2 or ATM Mutations
British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo. While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable. GSK's vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., the British drugmaker said in a statement.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
Investing.com – Stocks slumped Wednesday after the Federal Reserve cut its key interest rate to support the domestic economy amid slowing global growth, but Fed Chairman Jerome Powell indicated this was not the first cut of a monetary easing cycle.